Abstract
The inhibitory effects of thapsigargin, cyclopiazonic acid, and 2,5-di(tert-butyl)hydroquinone, and 1,3-dibromo-2,4,6-tri(methylisothiouronium)benzene on the Ca2+ ATPase were characterized by comparative measurements of sequential reactions of the catalytic and transport cycle, including biochemical measurements and detection of charge movements within a single cycle. In addition, patterns of ATPase proteolytic digestion with proteinase K were derived to follow conformational changes through the cycle or after inhibitor binding. We find that thapsigargin, cyclopiazonic acid, and 2,5-di(tert-butyl)hydroquinone inhibit Ca2+ binding and catalytic activation as demonstrated with isotopic tracers and lack of charge movement upon addition of Ca2+ in the absence of ATP. It has been shown previously that binding of these inhibitors requires the E2 conformational state of the ATPase, obtained in the absence of Ca2+. We demonstrate here that E2 state conformational features are in fact induced by these inhibitors on the ATPase even in the presence of Ca2+. The resulting dead-end complex interferes with progress of the catalytic and transport cycle. Inhibition by 1,3-dibromo-2,4,6-tri(methylisothiouronium)benzene, on the other hand, is related to interference with a conformational transition of the phosphorylated intermediate (E1∼P · 2Ca2+ to E2-P · 2Ca2+ transition), as demonstrated by increased phosphoenzyme levels and absence of bound Ca2+ translocation upon addition of ATP. This transition includes large movements of ATPase headpiece domains and transmembrane segments, produced through utilization of ATP-free energy as the “conformational work” of the pump. We conclude that the mechanism of high-affinity Ca2+ ATPase inhibitors is based on global effects on protein conformation that interfere with ATPase cycling.
Footnotes
-
This work was supported by the Ente Cassa di Risparmio di Firenze (PROMELAB project), the Ministero dell'Istruzione, dell'Università e della Ricerca (PRIN 2006), and the U.S. National Institutes of Health (R01-HL69830).
-
ABBREVIATIONS: TG, thapsigargin; CPA, cyclopiazonic acid; DBHQ, 2,5-di(tert-butyl)hydroquinone; TITU, 1,3-dibromo-2,4,6-tri(methylisothiouronium)benzene; SERCA, sarco-endoplasmic reticulum Ca2+ ATPase; SSM, solid supported membrane; MOPS, 3-(N-morpholino)propanesulfonic acid; SR, sarcoplasmic reticulum; DTT, dithiothreitol; conc., concentration.
- Received November 22, 2007.
- Accepted January 22, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|